Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States-Reference-Cited by-同舟云学术

Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States

Published:1994 Issue:2 Volume:6 Page:72-75
ISSN:0899-0042
Container-title:Chirality
language:en
Short-container-title:Chirality

Author:

Rauws Adalbert Gerard,Groen Kees

Publisher

Wiley

Subject

Organic Chemistry,Spectroscopy,Drug Discovery,Pharmacology,Catalysis,Analytical Chemistry

Reference10 articles.

1. FDA'S policy statement for the development of new stereoisomeric drugs

2. CPMP. Committee for Proprietary Medicinal Products. Document III/3501/91-EN, draft 13. Note for Guidance: ?Investigation of chiral active substances.? August 1993.

3. HPB. Health Protection Branch, Working Group on Drug Stereochemistry. Draft: Guidelines on the development of stereoisomeric drugs. October 1992.

4. Regulatory Requirements for Chiral Drugs

5. Spontaneous racemization of chlorthalidone: kinetics and activation parameters

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Valbenazine isomers and enantiomer determination by chiral normal phase liquid chromatography;Chirality;2023-06-21

2. Development, Robustness by Design Expert and Validation of a Method for Enantiomeric Impurity Content Determination in Pretomanid Drug Substance and Pharmaceutical Dosage Form;Journal of Chromatographic Science;2022-11-30

3. A simple and cost-effective synthesis of sulfated β-cyclodextrin and its application as chiral mobile phase additive in the separation of cloperastine enantiomers;Journal of Inclusion Phenomena and Macrocyclic Chemistry;2021-11-26

4. Recent Trends in Chiral Separations by 2D-HPLC;Chromatographia;2021-03-23

5. Development of an effective novel validated stability‐indicating HPLC method for the resolution of brivaracetam stereoisomeric impurities;Chirality;2020-07-13